

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book  
Search PubMed for amphiregulin and antibody and cancer Go Clear Save Search

Limits Preview/Index History Clipboard Details

Display Summary Show: 20 Sort Send to Text

About Entrez

Text Version

All: 31

Items 1 - 20 of 31

Page 1 of 2 Next

#### Entrez PubMed

Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

#### PubMed Services

Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
My NCBI (Cubby)

#### Related Resources

Order Documents  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

- ☐ 1: [Tanida S, Joh T, Itoh K, Kataoka H, Sasaki M, Ohara H, Nakazawa T, Nomura T, Kinugasa Y, Ohmoto H, Ishiguro H, Yoshino K, Higashiyama S, Itoh M.](#) Related Articles, Link



The mechanism of cleavage of EGFR ligands induced by inflammatory cytokines in gastric cancer cells.

Gastroenterology. 2004 Aug;127(2):559-69.

PMID: 15300588 [PubMed - indexed for MEDLINE]

- ☐ 2: [Hassan S, Dobner PR, Carraway RE.](#) Related Articles, Link



Involvement of MAP-kinase, PI3-kinase and EGF-receptor in the stimulatory effect of Neurotensin on DNA synthesis in PC3 cells.

Regul Pept. 2004 Aug 15;120(1-3):155-66.

PMID: 15177934 [PubMed - indexed for MEDLINE]

- ☐ 3: [Cho YM, Lewis DA, Koltz PF, Richard V, Gocken TA, Rosol TJ, Konger RL, Spandau DF, Foley J.](#) Related Articles, Link



Regulation of parathyroid hormone-related protein gene expression by epidermal growth factor-family ligands in primary human keratinocytes.

J Endocrinol. 2004 Apr;181(1):179-90.

PMID: 15072578 [PubMed - indexed for MEDLINE]

- ☐ 4: [Bostwick DG, Qian J, Maihle NJ.](#) Related Articles, Link



Amphiregulin expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 93 cases.

Prostate. 2004 Feb 1;58(2):164-8.

PMID: 14716741 [PubMed - indexed for MEDLINE]

- ☐ 5: [Gschwind A, Hart S, Fischer OM, Ullrich A.](#) Related Articles, Link



TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells.

EMBO J. 2003 May 15;22(10):2411-21.

PMID: 12743035 [PubMed - indexed for MEDLINE]

- ☐ 6: [Hurbin A, Dubrez L, Coll JL, Favrot MC.](#) Related Articles, Link











Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines.







J Biol Chem. 2002 Dec 20;277(51):49127-33. Epub 2002 Sep 27.

PMID: 12356750 [PubMed - indexed for MEDLINE]

- ☐ 7: [Silvy M, Giusti C, Martin PM, Berthois Y.](#) Related Articles, Link

-  Differential regulation of cell proliferation and protease secretion by epidermal growth factor and amphiregulin in tumoral versus normal breast epithelial cells.  
Br J Cancer. 2001 Apr 6;84(7):936-45.  
PMID: 11286474 [PubMed - indexed for MEDLINE]
- ☐ **8:** [el-Marjou A, Delougee A, Thiery JP, Radvanyi F.](#) Related Articles, Lin
-  Involvement of epidermal growth factor receptor in chemically induced mouse bladder tumour progression.  
Carcinogenesis. 2000 Dec;21(12):2211-8.  
PMID: 11133810 [PubMed - indexed for MEDLINE]
- ☐ **9:** [O-Charoenrat P, Rhys-Evans P, Eccles S.](#) Related Articles, Lin
-  Expression and regulation of c-ERBB ligands in human head and neck squamous carcinoma cells.  
Int J Cancer. 2000 Dec 1;88(5):759-65.  
PMID: 11072245 [PubMed - indexed for MEDLINE]
- ☐ **10:** [O-charoenrat P, Modjtahedi H, Rhys-Evans P, Court WJ, Box GM, Eccles SA.](#) Related Articles, Lin
-  Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.  
Cancer Res. 2000 Feb 15;60(4):1121-8.  
PMID: 10706134 [PubMed - indexed for MEDLINE]
- ☐ **11:** [Matsuura H, Sakaue M, Subbaramaiah K, Kamitani H, Eling TE, Dannenberg AJ, Tanabe T, Inoue H, Arata J, Jetten AM.](#) Related Articles, Lin
-  Regulation of cyclooxygenase-2 by interferon gamma and transforming growth factor alpha in normal human epidermal keratinocytes and squamous carcinoma cells. Role of mitogen-activated protein kinases.  
J Biol Chem. 1999 Oct 8;274(41):29138-48.  
PMID: 10506169 [PubMed - indexed for MEDLINE]
- ☐ **12:** [Sundareshan P, Nagle RB, Bowden GT.](#) Related Articles, Lin
-  EGF induces the expression of matrilysin in the human prostate adenocarcinoma cell line, LNCaP.  
Prostate. 1999 Aug 1;40(3):159-66.  
PMID: 10398277 [PubMed - indexed for MEDLINE]
- ☐ **13:** [Damstrup L, Kuwada SK, Dempsey PJ, Brown CL, Hawkey CJ, Poulsen HS, Wiley HS, Coffey RJ Jr.](#) Related Articles, Lin
-  Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis.  
Br J Cancer. 1999 Jun;80(7):1012-9.  
PMID: 10362109 [PubMed - indexed for MEDLINE]
- ☐ **14:** [Hisaka T, Yano H, Haramaki M, Utsunomiya I, Kojiro M.](#) Related Articles, Lin
-  Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: relationship to cell proliferation.  
Int J Oncol. 1999 Mar;14(3):453-60.  
PMID: 10024677 [PubMed - indexed for MEDLINE]
- ☐ **15:** [De Luca A, Casamassimi A, Selvam MP, Losito S, Ciardiello F, Agrawal S, Salomon DS, Normanno N.](#) Related Articles, Lin

EGF-related peptides are involved in the proliferation and survival of MDA

-  MB-468 human breast carcinoma cells.  
Int J Cancer. 1999 Feb 9;80(4):589-94.  
PMID: 9935161 [PubMed - indexed for MEDLINE]
- ☐ 16: [Normanno N, Bianco C, Damiano V, de Angelis E, Selvam MP, Grassi M, Magliulo G, Tortora G, Bianco AR, Mendelsohn J, Salomon DS, Ciardiello F.](#) [Related Articles](#), [Link](#)
-  Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides.  
Clin Cancer Res. 1996 Mar;2(3):601-9.  
PMID: 9816209 [PubMed - indexed for MEDLINE]
- ☐ 17: [Ma L, Gauville C, Berthois Y, Degeorges A, Millot G, Martin PM, Calvo F.](#) [Related Articles](#), [Link](#)
-  Role of epidermal-growth-factor receptor in tumor progression in transformed human mammary epithelial cells.  
Int J Cancer. 1998 Sep 25;78(1):112-9.  
PMID: 9724102 [PubMed - indexed for MEDLINE]
- ☐ 18: [Mincione G, Piccirelli A, Lazzereschi D, Salomon DS, Colletta G.](#) [Related Articles](#), [Link](#)
-  Heregulin-dependent autocrine loop regulates growth of K-ras but not erbB 2 transformed rat thyroid epithelial cells.  
J Cell Physiol. 1998 Aug;176(2):383-91.  
PMID: 9648926 [PubMed - indexed for MEDLINE]
- ☐ 19: [Ciardiello F, Tortora G.](#) [Related Articles](#), [Link](#)
-  Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications.  
Clin Cancer Res. 1998 Apr;4(4):821-8. Review.  
PMID: 9563874 [PubMed - indexed for MEDLINE]
- ☐ 20: [Ben-Bassat H, Rosenbaum-Mitrani S, Hartzstark Z, Shlomai Z, Kleinberger-Doron N, Gazit A, Plowman G, Levitzki R, Tsvieli R, Levitzki A.](#) [Related Articles](#), [Link](#)
-  Inhibitors of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes.  
Cancer Res. 1997 Sep 1;57(17):3741-50.  
PMID: 9288782 [PubMed - indexed for MEDLINE]



Items 1 - 20 of 31

Page 1 of 2 Next

Display	Summary	Show: 20	Sort	Send to: Text
---------	---------	----------	------	---------------

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)  
Department of Health & Human Services  
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Feb 23 2005 11:00:20



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book  
Search PubMed for amphiregulin and antibody and cancer Go Clear Save Search

Limits Preview/Index History Clipboard Details

Display Summary Show: 20 Sort Send to Text

About Entrez

Text Version

All: 31

Items 21 - 31 of 31

Previous Page 2 of

#### Entrez PubMed

Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

#### PubMed Services

Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
My NCBI (Cubby)

#### Related Resources

Order Documents  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

- ☐ 21: [Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, De Placido S, Mendelsohn J, Bianco AR, Tortora G.](#) Related Articles, Link

Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A.  
J Natl Cancer Inst. 1996 Dec 4;88(23):1770-6.  
PMID: 8944008 [PubMed - indexed for MEDLINE]

- ☐ 22: [Woodworth CD, Chung J, McMullin E, Plowman GD, Simpson S, Iglesias M.](#) Related Articles, Link

Transforming growth factor beta 1 supports autonomous growth of human papillomavirus-immortalized cervical keratinocytes under conditions promoting squamous differentiation.  
Cell Growth Differ. 1996 Jun;7(6):811-20.  
PMID: 8780894 [PubMed - indexed for MEDLINE]

- ☐ 23: [Piepkorn M.](#) Related Articles, Link

Overexpression of amphiregulin, a major autocrine growth factor for cultured human keratinocytes, in hyperproliferative skin diseases.  
Am J Dermatopathol. 1996 Apr;18(2):165-71.  
PMID: 8739992 [PubMed - indexed for MEDLINE]

- ☐ 24: [Beerli RR, Hynes NE.](#) Related Articles, Link

Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities.  
J Biol Chem. 1996 Mar 15;271(11):6071-6.  
PMID: 8626392 [PubMed - indexed for MEDLINE]






- ☐ 25: [Oikawa T, Hitomi J, Kono A, Kaneko E, Yamaguchi K.](#) Related Articles, Link

Frequent expression of genes for receptor tyrosine kinases and their ligands in human pancreatic cancer cells.  
Int J Pancreatol. 1995 Aug;18(1):15-23.  
PMID: 7594766 [PubMed - indexed for MEDLINE]

- ☐ 26: [Huang F, Sauma S, Yan Z, Friedman E.](#) Related Articles, Link

Colon absorptive epithelial cells lose proliferative response to TGF alpha as they differentiate.  
Exp Cell Res. 1995 Jul;219(1):8-14.  
PMID: 7628553 [PubMed - indexed for MEDLINE]

- ☐ 27: [Iglesias M, Plowman GD, Woodworth CD.](#) Related Articles, Link

-  Interleukin-6 and interleukin-6 soluble receptor regulate proliferation of normal, human papillomavirus-immortalized, and carcinoma-derived cervical cells in vitro.  
Am J Pathol. 1995 Apr;146(4):944-52.  
PMID: 7717461 [PubMed - indexed for MEDLINE]
- ☐ **28:** [Ebert M, Yokoyama M, Kobrin MS, Friess H, Lopez ME, Buchler MW, Johnson GR, Korc M.](#) Related Articles, Lin
-  Induction and expression of amphiregulin in human pancreatic cancer.  
Cancer Res. 1994 Aug 1;54(15):3959-62.  
PMID: 8033121 [PubMed - indexed for MEDLINE]
- ☐ **29:** [Qi CF, Liscia DS, Normanno N, Merlo G, Johnson GR, Gullick WJ, Ciardiello F, Saeki T, Brandt R, Kim N, et al.](#) Related Articles, Lin
-  Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas.  
Br J Cancer. 1994 May;69(5):903-10.  
PMID: 8180021 [PubMed - indexed for MEDLINE]
- ☐ **30:** [Li S, Plowman GD, Buckley SD, Shipley GD.](#) Related Articles, Lin
-  Heparin inhibition of autonomous growth implicates amphiregulin as an autocrine growth factor for normal human mammary epithelial cells.  
J Cell Physiol. 1992 Oct;153(1):103-11.  
PMID: 1522124 [PubMed - indexed for MEDLINE]
- ☐ **31:** [Johnson GR, Saeki T, Gordon AW, Shoyab M, Salomon DS, Stromberg K.](#) Related Articles, Lin
-  Autocrine action of amphiregulin in a colon carcinoma cell line and immunocytochemical localization of amphiregulin in human colon.  
J Cell Biol. 1992 Aug;118(3):741-51.  
PMID: 1639855 [PubMed - indexed for MEDLINE]

Items 21 - 31 of 31

Previous **Page** 2 of**Display** **Summary** Show: 20 Sort Send to: Text[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Department of Health &amp; Human Services

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Feb 23 2005 11:00:20

TYPE S9/MEDIUM, AB/1-17

**9/AB/1 (Item 1 from file: 5)**

DIALOG(R)File 5:Biosis Previews(R)  
(c) 2005 BIOSIS. All rts. reserv.

0011743978 BIOSIS NO.: 199900003638

**Human psoriatic skin in organ culture: Comparison with normal skin exposed to exogenous growth factors and effects of an antibody to the EGF receptor**

AUTHOR: Varani James (Reprint); Kang Sewon; Stoll Stefan; Elder James T  
AUTHOR ADDRESS: Dep. Pathology, Univ. Mich., 1301 Catherine Road, Box 0602,  
Ann Arbor, MI 48109, USA\*\*USA

JOURNAL: Pathobiology 66 (6): p253-259 Nov.-Dec., 1998 1998

MEDIUM: print

ISSN: 1015-2008

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

**ABSTRACT:** Organ cultures were established from psoriatic lesional skin of 24 different individuals and maintained for 8 days under serum-free, growth-factor-free conditions. Nonlesional skin from 14 of the same individuals and normal skin from another 12 individuals were also maintained in organ culture. At the end of the incubation period, the tissues were fixed in formalin and examined histologically. Lesional skin continued to express features of psoriatic plaque, which included irregularly shaped epithelial cells arranged in a disorganized fashion, and elongation of the rete ridges with a thickening in their lower portion. Abnormal epidermal differentiation and separation of the upper epidermal layers from the lower layers was also a consistent feature. In contrast, nonlesional skin from psoriatic patients exhibited a histological appearance which resembled that of site-matched normal skin. When normal skin was exposed to a growth-factor-enriched culture medium during the 8-day incubation period, it exhibited a histological appearance similar to that of psoriatic skin. In addition to abnormal histological features, the psoriatic skin in organ culture released higher amounts of matrix metalloproteinase-9 (MMP-9; 92kD gelatinase B/type IV collagenase) into the culture fluid than either nonlesional skin or normal skin. Organ cultures of psoriatic lesional skin from 6 individuals were maintained for 8 days in the presence of an antibody to the human epidermal growth-factor (EGF) receptor. The abnormal histological features of the psoriatic tissue were partially ameliorated in the presence of the antibody. These data suggest that growth factors which act through the EGF receptor help to maintain the psoriatic phenotype in organ culture. They also suggest that organ culture may provide a useful tool with which to elucidate the pathophysiological mechanisms of altered keratinocyte proliferation and differentiation in psoriasis.

**9/AB/2 (Item 2 from file: 5)**

DIALOG(R)File 5:Biosis Previews(R)  
(c) 2005 BIOSIS. All rts. reserv.

0009892592 BIOSIS NO.: 199598360425

**Immunolocalization of epidermal growth factor and epidermal growth factor receptors in psoriatic epidermis**

AUTHOR: Liu Baojun; Zhang; Haitao; Li; Shuqin

AUTHOR ADDRESS: Shenyang Military General Hosp., Shenyang 110015, China\*\*

China

JOURNAL: Zhonghua Pifuke Zazhi 28 (2): p67-69 1995 1995

ISSN: 0412-4030

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: Chinese

ABSTRACT: We used an avidin-biotin-complex immunoperoxidase technique with anti-epidermal growth factor (EGF) polyclonal antibody and anti-EGF receptors (EGFR) monoclonal antibody to investigate the skin lesions from 20 patients with psoriasis vulgaris and normal skin from 10 healthy volunteers. Our results showed that: (1) The immunoreactive proteins of EGF and EGFR were primarily restricted to the basal cells and suprabasal keratinocytes in both normal epidermis and uninvolved psoriatic epidermis; (2) EGF and EGFR were distributed in all epidermal layers of active psoriatic lesions, and elevated levels of EGF and EGFR were seen in the mid and upper epidermal layers; (3) The immunoreactive proteins of EGF and EGFR were absent in the stratum corneum and decreased in the upper epidermal layers in regressing psoriatic lesions. It is suggested that EGF and EGFR may play an important role in the hyperproliferation and abnormal differentiation of keratinocytes seen in psoriasis.

9/AB/3 (Item 3 from file: 5)

DIALOG(R) File 5: Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0009351105 BIOSIS NO.: 199497372390

**PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: A possible cellular basis for remittive therapy**

AUTHOR: Vallat Val Pierre; Gilleaudeau Patricia; Battat Lisa; Wolfe Jonathan; Nabeya Reiko; Heftler Noah; Hodak Emmilia; Gottlieb Alice B (Reprint); Krueger James G

AUTHOR ADDRESS: Rockefeller Univ., 1230 York Ave., Box 178, New York, NY 10021-6399, USA\*\*USA

JOURNAL: Journal of Experimental Medicine 180 (1): p283-296 1994 1994

ISSN: 0022-1007

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Psoriasis is characterized by alterations in both the epidermis and dermis of the skin. Epidermal keratinocytes display marked proliferative activation and differentiate along an "alternate" or "regenerative" pathway, while the dermis becomes infiltrated with leukocytes, particularly interleukin 2 (IL-2) receptor-bearing "activated" T cells. Psoralens, administered by the oral route, have therapeutic effects in psoriasis when photochemically activated by ultraviolet A light (PUVA therapy). Recently psoralen bath therapy has been introduced to more effectively deliver this agent to the diseased skin. We have correlated the efficacy of PUVA bath therapy with its effects on specific molecular and cellular parameters of disease, in 10 consecutive patients with recalcitrant psoriasis. Rapid clearing of lesions occurred in 8 out of 10 patients. Biopsies were taken from lesional and nonlesional skin before and after a single round of therapy, and observation was continued in our Clinical Research Center at The Rockefeller University. Enumeration of cycling keratinocytes with the Ki-67 monoclonal antibody showed that PUVA reduced cell proliferation by 73%. The pathological increase in insulin-like growth factor 1 (IGF-1) receptors was reversed, whereas epidermal growth factor (EGF) receptors,

which are also increased in psoriasis, remained unchanged. Keratinocyte proteins that are expressed in abnormal sites of the epidermis during psoriasis, i.e., keratin 16, filaggrin, and involucrin, were, after PUVA treatment, localized to their normal sites. Epidermal and dermal T-lymphocytes (CD3+), as well as CD4+, CD8+, and IL-2 receptor+ subsets, were strongly suppressed by PUVA, with virtual elimination of IL-2 receptor+ T cells in some patients. Consistent with diminished lymphocyte activation, HLA-DR expression by epidermal keratinocytes was markedly reduced in treated skin. In comparison to cyclosporine treatment of psoriasis, PUVA therapy leads to more complete reversal of pathological epidermal and lymphocytic activation, changes which we propose to be the cellular basis for a more sustained remission of disease after PUVA treatment.

**9/AB/4 (Item 4 from file: 5)**

DIALOG(R)File 5:BIOSIS Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0009119715 BIOSIS NO.: 199497141000

**Localization of annexins in normal and diseased human skin**

AUTHOR: Bastian Boris C (Reprint); Van Der Piepen Ute; Roemisch Juergen; Paques Eric-P; Broecker Eva-Bettina

AUTHOR ADDRESS: Dep. Dermatol., Univ. Wurzburg, Med.

Sch., Josef-Schneider-Str. 2, D-97080 Wurzburg, Germany\*\*Germany

JOURNAL: Journal of Dermatological Science 6 (3): p225-234 1993 1993

ISSN: 0923-1811

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

**ABSTRACT:** Annexins (AX) or lipocortins are a family of calcium and phospholipid binding proteins that have been implicated to play a role in the regulation of inflammation and cellular differentiation. To investigate a potential role of AX in skin disorders we studied the distribution of six different AX in normal human skin (NHS) and several inflammatory and hyperproliferative skin diseases. A distinct staining pattern could only be shown for AX-1 and AX-2. In NHS AX1-antibody (Ab) displayed a very strong reactivity with eccrine sweat ducts. In the diseases investigated we found a highly increased expression of AX-1 in keratinocytes (KCs) in the vicinity of inflammatory processes such as psoriasis. Furthermore, the AX-1 expression was increased in differentiated squamous cell carcinoma (SCC) whereas undifferentiated SCC and basal cell carcinoma were negative. AX-3, -4, -5, and -6 showed no distinctive expression pattern. Our data demonstrate an abnormal distribution of AX-1 in association with proliferating KCs under inflammatory and neoplastic conditions. Its pattern of reactivity shows similarities to the known distribution of the EGF-receptor kinase, which has been demonstrated to phosphorylate AX-1 with high activity in various cellular systems. These results support the concept that the appearance of AX-1 is linked to a certain level of KC differentiation.

**9/AB/5 (Item 5 from file: 5)**

DIALOG(R)File 5:BIOSIS Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0008760409 BIOSIS NO.: 199395062675

**Induction of human microvascular endothelial tubular morphogenesis by human keratinocytes: Involvement of transforming growth factor-alpha**



AUTHOR: Ono Mayumi (Reprint); Okamura Kazuki (Reprint); Nakayama Yoshifumi (Reprint); Tomita Mika; Sato Yasufumi (Reprint); Komatsu Yasuhiro; Kuwano Michihiko (Reprint)  
AUTHOR ADDRESS: Dep. Biochem., Oita Med. Univ., Hasama-machi, Oita 879-55, Japan\*\*Japan  
JOURNAL: Biochemical and Biophysical Research Communications 189 (2): p 601-609 1992  
ISSN: 0006-291X  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: Transforming growth factor-alpha(TGF-alpha), homologous to epidermal growth factor(EGF), is closely involved in hyperproliferation of human keratinocytes. Psoriasis is a common hyperproliferative skin disease characterized by hyperproliferation of keratinocytes and abnormal development of dermal capillary networks. In this study, we have examined whether keratinocytes could enhance angiogenesis. TGF-alpha or EGF efficiently stimulated formation of tubular-like structures of human omental microvascular endothelial (HOME) cells in type I collagen gels. Human keratinocytes produce TGF-alpha. To examine whether co-cultured keratinocytes could induce tubulogenesis of HOME cells in collagen gel, we have developed a co-culture system with human keratinocytes. Surprisingly, there appeared new development of many tubular-like structures of HOME cells in collagen gels when co-cultured with keratinocytes. This keratinocytes-dependent tubulogenesis was almost completely blocked when anti-TGF-alpha-antibody was present. The TGF-alpha molecules derived from keratinocytes appeared to enhance tubulogenesis of human microvascular endothelial cells. We propose the hypothesis that secretory TGF-alpha from human keratinocytes may promote an autocrine loop to proliferate the skin keratinocytes and also a paracrine loop to induce the skin angiogenesis.

9/AB/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2005 BIOSIS. All rts. reserv.

0008419006 BIOSIS NO.: 199294120847

**MOLECULAR CLONING AND EXPRESSION OF A NOVEL KERATINOCYTE PROTEIN  
PSORIASIS-ASSOCIATED FATTY ACID-BINDING PROTEIN PA-FABP THAT IS HIGHLY  
UP-REGULATED IN PSORIATIC SKIN AND THAT SHARES SIMILARITY TO FATTY  
ACID-BINDING PROTEINS**

AUTHOR: MADSEN P (Reprint); RASMUSSEN H H; LEFFERS H; HONORE B; CELIS J E  
AUTHOR ADDRESS: INST MED BIOCHEM, DANISH CENT HUMAN GENOME RES, OLE WORMS  
ALLE, BUILDING 170, UNIVERSITY PARK, DK-8000 AARHUS C, DENMARK\*\*DENMARK  
JOURNAL: Journal of Investigative Dermatology 99 (3): p299-305 1992  
ISSN: 0022-202X  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

ABSTRACT: Analysis by means of two-dimensional (2D) gel electrophoresis of the protein patterns of normal and psoriatic unfractionated non-cultured keratinocytes has revealed a few low-molecular-weight proteins that are highly up-regulated in psoriatic skin. These include psoriasin; calgranulin B, also known as MRP 14, L1, or calprotectin; calgranulin A or MRP 8; and cystatin A or stefin A. Here, we have cloned and sequenced the cDNA (clone 1592) encoding a new member of this group of low-molecular-weight proteins [isoelectric focusing (IEF) SSP 3007 in the

keratinocyte 2D gel protein database] that we have termed PA-FABP (psoriasis-associated fatty acid-binding protein). The deduced sequence predicted a protein with molecular weight of 15,164 daltons and a calculated pI of 6.96, values that are close to those recorded in the keratinocyte 2D gel protein database. The protein comigrated with PA-FABP as determined by 2D gel analysis of [<sup>35</sup>S]-methionine-labeled proteins expressed by transformed human amnion (AMA) cells transfected with clone 1592 using the vaccinia virus expression system and reacted with a rabbit polyclonal antibody raised against 2D gel purified PA-FABP. Structural analysis of the amino acid sequence revealed 48%, 52%, and 56% identity to known low-molecular-weight fatty acid-binding proteins belonging to the FABP family. Northern blot analysis showed that PA-FABP mRNA is indeed highly up-regulated in psoriatic keratinocytes. The transcript is present in human cell lines of epithelial and lymphoid (Molt 4) origin but cannot be detected in normal or SV40 transformed MRC-5 fibroblasts. 2D gel protein analysis of normal primary keratinocytes cultured for at least 8 d under conditions that promoted incomplete terminal differentiation [serum-free keratinocyte (SKF) medium supplemented with epidermal growth factor (EGF), pituitary extract, and 10% fetal calf serum] revealed a strong up-regulation of PA-FABP, psoriasin, calgranulins A and B, and a few other proteins that are highly expressed in psoriatic skin. The levels of these proteins exceeded by far those observed in non-cultured normal keratinocytes implying that the cultured cells have followed an altered pattern of differentiation that resembles - at least in part - that of non-cultured psoriatic keratinocytes. The implications of these results for the study of psoriasis are discussed.

9/AB/7 (Item 7 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0008301674 BIOSIS NO.: 199294003515

**THE INSULIN-LIKE GROWTH FACTOR I RECEPTOR IS OVEREXPRESSED IN PSORIATIC EPIDERMIS BUT IS DIFFERENTIALLY REGULATED FROM THE EPIDERMAL GROWTH FACTOR RECEPTOR**

AUTHOR: KRANE J F (Reprint); GOTTLIEB A B; CARTER D M; KRUEGER J G

AUTHOR ADDRESS: LAB INVEST DERMATOL, ROCKEFELLER UNIV, 1230 YORK AVE, NEW YORK, NY 10021, USA\*\*USA

JOURNAL: Journal of Experimental Medicine 175 (4): p1081-1090 1992

ISSN: 0022-1007

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

**ABSTRACT:** Insulin-like growth factor I (IGF-I)/somatomedin C is an important mediator of keratinocyte growth in vitro, and the expression of IGF-I receptors in the basal layer of normal epidermis suggests that this growth pathway may function in the regulation of keratinocyte growth in vivo as well. The pattern of IGF-I receptor expression in normal skin is distinct from that of the epidermal growth factor (EGF) receptor, suggesting that these receptors might be differentially regulated. The purpose of this study was to obtain a better understanding of IGF-I receptor function in the skin by examining IGF-I receptor expression in psoriatic epidermis and in cultured human keratinocytes. Our findings indicate that IGF-I receptor expression is increased in psoriasis as measured by protein tyrosine kinase assays of biopsy extracts and by immunohistochemical staining with an IGF-I receptor-specific monoclonal antibody. Unlike EGF receptor expression, which is also increased in psoriatic epidermis, the pattern of IGF-I receptor expression corresponds

closely with the increased size of the keratinocyte proliferative compartment in psoriasis. Biochemical agents that diminish EGF receptor ligand binding (phorbol ester or calcium ionophore treatment) produce opposite effects on the IGF-I receptor. These results suggest that cellular expression and differential regulation of both growth factor receptor systems may control critical aspects of epidermal proliferation or function.

9/AB/8 (Item 8 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2005 BIOSIS. All rts. reserv.

0006590332 BIOSIS NO.: 198987038223

**DISTRIBUTION OF EGF RECEPTOR EXPRESSING AND DNA REPLICATING EPIDERMAL CELLS IN PSORIASIS VULGARIS AND BOWEN'S DISEASE**

AUTHOR: AMAGAI M (Reprint); OZAWA S; UEDA M; NISHIKAWA T; ABE O; SHIMIZU N  
AUTHOR ADDRESS: DEP MOL BIOL, KEIO UNIV SCH MED, 35 SHINANOMACHI,  
SHINJUKU-KU, TOKYO 160, JPN\*\*JAPAN

JOURNAL: British Journal of Dermatology 119 (5): p661-668 1988

ISSN: 0007-0963

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: We have examined the localization of DNA replicating cells and EGE receptor-expressing cells in the epidermis of psoriasis vulgaris, a benign hyperproliferative skin disease, and Bowen's disease, a pre-malignant hyperproliferative skin disease, and normal skin. DNA replicating cells were detected by anti-BrdU monoclonal antibody after incubating tissue sections with BrdU, and EGF receptors were detected by the anti-EGF receptor monoclonal antibody B4G7. In normal skin, DNA replicating cells were localized exclusively in the basal and suprabasal layers. EGF receptor expression was observed most strongly in the basal and parabasal layers, but diminished gradually towards the upper squamous layer. In psoriatic skin, DNA replicating cells were also localized in the basal and parabasal layers, but the number of these mitotic cells was about 10 times higher than in normal skin. In this case, more EGF receptors were detected in all viable layers of the epidermis. Apparently normal skin adjacent to psoriasis lesions showed persistent expression of EGF receptors in the upper squamous later without an increased number of DNA replicating cells in the basal and parabasal layers. In Bowen's disease, DNA replicating cells and EGF receptor expressing cells were distributed in all layers of the epidermis. These findings indicate that the increased production of EGF receptors may be, in part, responsible for the hyperproliferative state of the epidermis and that cells in the upper squamous layer of psoriasis may have lost a mechanism by which EGF receptor expression is diminished thus allowing differentiation. This altered process of EGF receptor production may be involved in the onset of psoriasis vulgaris.

9/AB/9 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2005 Elsevier Science B.V. All rts. reserv.

12713145 EMBASE No: 2004310856

**In this issue**

Elder J.T.

J.T. Elder, University of Michigan, Medical Center, Ann Arbor Veterans

Affairs Hospital, Ann Arbor, MI United States  
Journal of Investigative Dermatology ( J. INVEST. DERMATOL. ) (United States) 2004, 123/2 (vi-vii)  
CODEN: JIDEA ISSN: 0022-202X  
DOCUMENT TYPE: Journal ; Editorial  
LANGUAGE: ENGLISH

**9/AB/10 (Item 2 from file: 73)**  
DIALOG(R)File 73:EMBASE  
(c) 2005 Elsevier Science B.V. All rts. reserv.

06467279 EMBASE No: 1996132953

**Overexpression of amphiregulin, a major autocrine growth factor for cultured human keratinocytes, in hyperproliferative skin diseases**

Piepkorn M.

Dermatology Division, University of Washington, Box 356524 Health Sciences, Seattle, WA 98195 United States

American Journal of Dermatopathology ( AM. J. DERMATOPATHOL. ) (United States) 1996, 18/2 (165-171)

CODEN: AJDOD ISSN: 0193-1091

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Previous studies have indicated that amphiregulin is a major autocrine growth factor for cultured human keratinocytes. Its overexpression could therefore be important in hyperproliferative skin diseases. The purpose of this preliminary study was to determine if there is upregulation of amphiregulin protein in those disorders. A variety of lesions was surveyed for qualitative alterations in its immunostaining with an anti-amphiregulin monoclonal antibody. Amphiregulin was barely detectable in the epidermis of normal controls, although there was random nuclear staining of keratinocytes, and the epidermal appendages, especially sebaceous glands, were usually reactive. In contrast, psoriatic lesions exhibited prominent cytoplasmic staining of basal and spinous keratinocytes. Somewhat increased reactivity was also evident in actinic keratoses, in nests of squamous carcinoma cells, and in verrucae. Adnexal tumors were often strongly stained. Whereas basal cell carcinomas were nonreactive, staining was present in adjacent epidermis. Similarly, the melanocytes of nevi and melanoma were nonreactive but there was increased staining in contiguous keratinocytes. The pattern of amphiregulin immunostaining suggests a role for the protein in the aberrant keratinocyte growth of hyperproliferative disorders.

**9/AB/11 (Item 3 from file: 73)**  
DIALOG(R)File 73:EMBASE  
(c) 2005 Elsevier Science B.V. All rts. reserv.

06033610 EMBASE No: 1995063848

**Cd44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor**

Bennett K.L.; Jackson D.G.; Simon J.C.; Tanczos E.; Peach R.; Modrell B.; Stamenkovic I.; Plowman G.; Aruffo A.

B. M. Squibb Pharmaceut. Res. Inst., 3005 First Avenue, Seattle, WA 98121 United States

Journal of Cell Biology ( J. CELL BIOL. ) (United States) 1995, 128/4 (687-698)

CODEN: JCLBA ISSN: 0021-9525

DOCUMENT TYPE: Journal; Article

Glycosaminoglycan-modified isoforms of CD44 have been implicated in growth factor presentation at sites of inflammation. In the present study we show that COS cell transfectants expressing CD44 isoforms containing the alternatively spliced exon V3 are modified with heparan sulfate (HS). Binding studies with three HS-binding growth factors, basic-fibroblast growth factor (b-FGF), heparin binding-epidermal growth factor (HB-EGF), and amphiregulin, showed that the HS-modified CD44 isoforms are able to bind to b-FGF and HB-EGF, but not AR. b-FGF and HB-EGF binding to HS-modified CD44 was eliminated by pretreating the protein with heparitinase or by blocking with free heparin. HS-modified CD44 immunoprecipitated from keratinocytes, which express a CD44 isoform containing V3, also bound to b-FGF. We examined whether HS-modified CD44 isoforms were expressed by activated endothelial cells where they might present HS-binding growth factors to leukocytes during an inflammatory response. PCR and antibody-binding studies showed that activated cultured endothelial cells only express the CD44H isoform which does not contain any of the variably spliced exons including V3. Immunohistological studies with antibodies directed to CD44 extracellular domains encoded by the variably spliced exons showed that vascular endothelial cells in inflamed skin tissue sections do not express CD44 spliced variants. Keratinocytes, monocytes, and dendritic cells in the same specimens were found to express variably spliced CD44. <sup>3</sup>S-<sup>35</sup>S-labeling experiments demonstrated that activated cultured endothelial cells do not express detectable levels of chondroitin sulfate or HS-modified CD44. Our results suggest that one of the functions of CD44 isoforms expressing V3 is to bind and present a subset of HS-binding proteins. Furthermore, it is probable that HS-modified CD44 is involved in the presentation of HS-binding proteins by keratinocytes in inflamed skin. However, our data suggests that CD44 is not likely to be the proteoglycan principally involved in presenting HS-binding growth factors to leukocytes on the vascular cell wall.

9/AB/12 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2005 The Dialog Corp. All rts. reserv.

09602687 PMID: 1836217

**Lipocortin I (annexin I) is preferentially localized on the plasma membrane in keratinocytes of psoriatic lesional epidermis as shown by immunofluorescence microscopy.**

Kitajima Y; Owada M K; Mitsui H; Yaoita H

Department of Dermatology, Jichi Medical School, Tochigiken, Japan.

Journal of investigative dermatology (UNITED STATES) Dec 1991, 97 (6)

p1032-8, ISSN 0022-202X Journal Code: 0426720

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Lipocortin I (LPC-I, also called annexin I) is a 35-kD protein that binds phospholipids and actin in a Ca(++)-dependent manner. It is also a major substrate for EGF receptor/kinase and protein kinase C, and a putative inhibitor of phospholipase A2, which produces chemical mediators to cause inflammation. Psoriasis (PS) is an inflammatory skin disease characterized by a rapid turnover of keratinocytes and a defect in keratinization with increased activities of phospholipase C and A2, and EGF receptor. To understand the mechanism of the PS lesion formation and the function of

LPC-I, its distribution was studied in the epidermis of PS, subacute eczema and normal skin, and in tumor cells of seborrheic keratosis and Bowen's disease. This study involved immunofluorescence and immunoblotting using affinity-purified polyclonal and monoclonal antibodies specific to LPC-I and to its Ca(++)-bound form. In normal, nonlesional PS and subacute eczema epidermis, LPC-I was detected mainly in the cytoplasm of the suprabasal cells, although it was on the inner aspects of the plasma membrane in some parts of the granular layer. In lesional epidermis of PS, it was localized mainly on the inner aspects of the plasma membrane, but not in the cytoplasm of the whole suprabasal cells as the Ca(++)-bound form, indicating a preferential localization on the plasma membrane. This membrane-binding of LPC-I was also observed in seborrheic keratosis, but not in Bowen's disease. These results suggest that the binding of LPC-I to the plasma membrane occurs actually in living cells, plays a role, not necessarily disease specific, in the PS lesion formation, and has some relevance to normal or abnormal differentiation of keratinocytes.

9/AB/13 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2005 The Dialog Corp. All rts. reserv.

08213374 PMID: 3279155

**Detection of transforming growth factor alpha in normal, malignant, and hyperproliferative human keratinocytes.**

Gottlieb A B; Chang C K; Posnett D N; Fanelli B; Tam J P

Laboratory of Immunology, Rockefeller University, New York.

Journal of experimental medicine (UNITED STATES) Feb 1 1988, 167 (2)  
p670-5, ISSN 0022-1007 Journal Code: 2985109R

Contract/Grant No.: AI-19080; AI; NIAID; AR-35676; AR; NIAMS; CA-42046;  
CA; NCI; +

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Transforming growth factor alpha (TGF-alpha) is a 50-amino acid peptide, previously demonstrated only in transformed cell lines and human tumors, which is structurally homologous to epidermal growth factor (EGF). TGF-alpha expression in keratinocytes from normal individuals, patients with psoriasis, and patients with malignant skin diseases was investigated using an mAb raised against synthetic human TGF-alpha. mAb A1.5 reacted with TGF-alpha, but not EGF, in a sensitive ELISA. Keratinocytes in eight nodular basal cell carcinomas, one morpheic basal cell carcinoma, and one squamous cell carcinoma demonstrated intense membranous immunoperoxidase staining with mAb A1.5. Of even greater interest was the observation that the overlying normal epidermis, as well as the epidermis from five normal skin specimens, were stained by the mAb. Keratinocytes in plaques from 18 psoriasis patients were more intensely stained than those from normal skin. Cultured normal keratinocytes demonstrated membranous staining with mAb A1.5. Absorption of mAb A1.5 with synthetic human TGF-alpha completely removed the reactivity of mAb A1.5 with both basal cell tumors and normal epidermis. The demonstration of TGF-alpha in normal keratinocytes suggests that it plays a role in normal keratinocyte growth, wound healing, and in the pathogenesis of acanthosis.

9/AB/14 (Item 1 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

141189645 CA: 141(12)189645h PATENT

Humanized or chimeric anti-amphiregulin antibodies, fragments and immunoconjugates for treat cancer or proliferative disease and psoriasis  
INVENTOR(AUTHOR): Landolfi, Nicholas F.; Tsurushita, Naoya; Hinton, Paul R.; Kumar, Shankar

LOCATION: USA

ASSIGNEE: Protein Design Labs Inc.

PATENT: PCT International ; WO 200468931 A2 DATE: 20040819

APPLICATION: WO 2004US4176 (20040206) \*US PV445640 (20030207) \*US PV533901 (20031230)

PAGES: 99 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-031/00A

DESIGNATED COUNTRIES: AE; AE; AG; AL; AL; AM; AM; AM; AT; AT; AU; AZ; AZ; BA; BB; BG; BG; BR; BR; BW; BY; BY; BZ; BZ; CA; CH; CN; CN; CO; CO; CR; CR; CU; CU; CZ; CZ; DE; DE; DK; DK; DM; DZ; EC; EC; EE; EE; EG; ES; ES; FI; FI; GB; GD; GE; GE; GH; GM; HR; HR; HU; HU; ID; IL; IN; IS; JP; JP; KE; KE; KG; KG; KP; KP; KP; KR; KR; KZ; KZ; KZ; LC; LK; LR; LS; LS; LT; LU; LV; MA; MD; MD; MG; MK; MN; MW; MX; MX; MZ; MZ; NA; NI DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

9/AB/15 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

139212354 CA: 139(14)212354g PATENT

Methods and compositions for the therapeutic use of contact inhibitory factor (CIF)

INVENTOR(AUTHOR): Lipkin, George; Rosenberg, Martin Jay

LOCATION: USA

ASSIGNEE: New York University

PATENT: PCT International ; WO 200372737 A2 DATE: 20030904

APPLICATION: WO 2003US5563 (20030224) \*US PV359053 (20020222) \*US PV386570 (20020605)

PAGES: 26 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

9/AB/16 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

136161345 CA: 136(11)161345h PATENT

Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists

INVENTOR(AUTHOR): Teufel, Thomas

LOCATION: USA

ASSIGNEE: Imclone Systems Incorporated

PATENT: PCT International ; WO 200211677 A2 DATE: 20020214

APPLICATION: WO 2001US41647 (20010809) \*US 635974 (20000809)  
 PAGES: 28 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-000/A  
 DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
 CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;  
 GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;  
 LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI;  
 SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG;  
 KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ;  
 ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC;  
 NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD;  
 TG

9/AB/17 (Item 4 from file: 399)  
 DIALOG(R) File 399:CA SEARCH(R)  
 (c) 2005 American Chemical Society. All rts. reserv.

124340904 CA: 124(25)340904p PATENT  
**Methods and bifunctional ligands for specific tumor inhibition by blood  
 coagulation in tumor vasculature**  
 INVENTOR(AUTHOR): Thorpe, Philip E.; Edgington, Thomas S.  
 LOCATION: USA  
 ASSIGNEE: Univ. of Texas System; Scripps Res. Inst.  
 PATENT: PCT International ; WO 9601653 A1 DATE: 960125  
 APPLICATION: WO 95US7439 (950607) \*US 273567 (940711)  
 PAGES: 325 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-047/48A  
 DESIGNATED COUNTRIES: AM; AT; AU; BB; BG; BR; BY; CA; CH; CN; CZ; DE; DK;  
 EE; ES; FI; GB; GE; HU; IS; JP; KE; KG; KP; KR; KZ; LK; LR; LT; LU; LV; MD;  
 MG; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; TJ; TT; UA  
 DESIGNATED REGIONAL: KE; MW; SD; SZ; UG; AT; BE; CH; DE; DK; ES; FR; GB;  
 GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE;  
 SN; TD; TG  
 ?

Set	Items	Description
S1	68289	EGF
S2	68894	S1 OR AMPHIREGULIN
S3	3056	S2 AND HEPARIN
S4	371	S3 AND ANTIBODY
S5	2	S4 AND PSORIASIS
S6	68972	S2 OR HEPARIN BINDING
S7	6249	S6 AND ANTIBODY
S8	34	S7 AND PSORIASIS
S9	17	RD S8 (unique items)
?		



Day : Thursday  
Date: 2/24/2005


**PALM INTRANET**

Time: 12:23:04

**Inventor Name Search Result**

Your Search was:

Last Name = LANDOLFI

First Name = NICHOLAS

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<u>09718993</u>	Not Issued	161	11/22/2000	HUMANIZED IMMUNOGLOBULINS	LANDOLFI, NICHOLAS F.
<u>09718998</u>	Not Issued	041	11/22/2000	HUMANIZED IMMUNOGLOBULINS	LANDOLFI, NICHOLAS F.
<u>09992524</u>	Not Issued	071	11/13/2001	HUMANIZED ANTIBODIES TO GAMMA-INTERFERON	LANDOLFI, NICHOLAS F.
<u>10389155</u>	Not Issued	030	03/13/2003	HUMANIZED IMMUNOGLOBULINS	LANDOLFI, NICHOLAS F.
<u>10389417</u>	Not Issued	030	03/13/2003	HUMANIZED IMMUNOGLOBULINS	LANDOLFI, NICHOLAS F.
<u>10394458</u>	Not Issued	168	03/20/2003	HUMANIZED IMMUNOGLOBULINS	LANDOLFI, NICHOLAS F.
<u>10452357</u>	Not Issued	030	05/30/2003	HUMANIZED IMMUNOGLOBULINS	LANDOLFI, NICHOLAS F.
<u>10774076</u>	Not Issued	071	02/06/2004	AMPHIREGULIN ANTIBODIES AND THEIR USE TO TREAT CANCER AND PSORIASIS	LANDOLFI, NICHOLAS F.
<u>10842011</u>	Not Issued	030	05/07/2004	THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES	LANDOLFI, NICHOLAS F.
<u>07532267</u>	Not Issued	166	06/01/1990	CHIMERIC LIGAND/IMMUNOGLOBULIN MOLECULES AND THEIR USES	LANDOLFI, NICHOLAS F.
<u>07728962</u>	Not Issued	161	07/12/1991	PRODUCTION OF HUMAN ANTIBODIES	LANDOLFI, NICHOLAS F.
<u>07983949</u>	Not Issued	166	12/01/1992	HUMANIZED ANTIBODIES REACTIVE WITH CD18	LANDOLFI, NICHOLAS F.
<u>08076263</u>	<u>5349053</u>	250	06/10/1993	CHIMERIC LIGAND/IMMUNOGLOBULIN MOLECULES AND THEIR USES	LANDOLFI, NICHOLAS F.
<u>08304646</u>	Not Issued	161	09/12/1994	HUMANIZED ANTIBODIES REACTIVE WITH CD18	LANDOLFI, NICHOLAS F.
<u>08477728</u>	<u>5585089</u>	150	06/07/1995	HUMANIZED	LANDOLFI,

				IMMUNOGLOBULINS	NICHOLAS F.
<u>08484537</u>	<u>6180370</u>	150	06/07/1995	HUMANIZED IMMINOGLOBULINS AND METHODS OF MAKING THE SAME	LANDOLFI, NICHOLAS F.
<u>08487200</u>	<u>5693762</u>	150	06/07/1995	HUMANIZED IMMUNOGLOBULINS	LANDOLFI, NICHOLAS F.
<u>08621751</u>	<u>5882644</u>	150	03/22/1996	MONOCLONAL ANTIBODIES SPECIFIC FOR THE PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR AND METHODS OF USE THEREOF	LANDOLFI, NICHOLAS F.
<u>09325000</u>	Not Issued	168	06/01/1999	HUMANIZED IMMUNOGLOBULINS	LANDOLFI, NICHOLAS F.
<u>09450520</u>	<u>6329511</u>	150	11/29/1999	HUMANIZED ANTIBODIES TO GAMMA-INTERFERON	LANDOLFI, NICHOLAS F.
<u>60110523</u>	Not Issued	159	12/01/1998	HUMANIZED ANTIBODIES TO GAMMA-INTERFERON	LANDOLFI, NICHOLAS F.

Inventor Search Completed: No Records to Display.

<b>Search Another: Inventor</b>	<b>Last Name</b>	<b>First Name</b>	<input type="button" value="Search"/>
	<input type="text" value="landolfi"/>	<input type="text" value="nicholas"/>	

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Day : Thursday  
Date: 2/24/2005


**PALM INTRANET**

Time: 12:23:56

**Inventor Name Search Result**

Your Search was:

Last Name = TSURUSHITA

First Name = NAOYA

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<u>07988255</u>	Not Issued	161	12/09/1992	CONSTRUCTION OF HUMAN IMMUNOGLOBULIN COMBINATORIAL LIBRARY BASED ON ARTIFICIAL V GENES COMPRISING GENOMIC V SEGMENTS AND SYNTHETIC CDR3 FRAGMENTS	TSURUSHITA, NAOYA
<u>09450520</u>	<u>6329511</u>	150	11/29/1999	HUMANIZED ANTIBODIES TO GAMMA-INTERFERON	TSURUSHITA, NAOYA
<u>09772103</u>	Not Issued	071	01/26/2001	ANTIBODIES AGAINST CTLA4 AND USES THEREFOR	TSURUSHITA, NAOYA
<u>09992524</u>	Not Issued	071	11/13/2001	HUMANIZED ANTIBODIES TO GAMMA-INTERFERON	TSURUSHITA, NAOYA
<u>10226435</u>	Not Issued	080	08/22/2002	HUMANIZED ANTIBODIES THAT SEQUESTER ABETA PEPTIDE	TSURUSHITA, NAOYA
<u>10371483</u>	Not Issued	030	02/21/2003	ANTI-CCR5 ANTIBODY	TSURUSHITA, NAOYA
<u>10476265</u>	Not Issued	030	10/22/2003	HUMANIZED ANTIBODIES	TSURUSHITA, NAOYA
<u>10484280</u>	Not Issued	030	01/15/2004	INTERLEUKIN-1 BETA ANTIBODIES	TSURUSHITA, NAOYA
<u>10486908</u>	Not Issued	030	02/17/2004	ASSAY METHOD FOR ALZHEIMER'S DISEASE	TSURUSHITA, NAOYA
<u>10487322</u>	Not Issued	030	02/17/2004	ANTI-ABETA ANTIBODIES	TSURUSHITA, NAOYA
<u>10687118</u>	Not Issued	030	10/15/2003	ALTERATION OF FCRN BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS	TSURUSHITA, NAOYA

<u>10774076</u>	Not Issued	071	02/06/2004	AMPHIREGULIN ANTIBODIES AND THEIR USE TO TREAT CANCER AND PSORIASIS	TSURUSHITA, NAOYA
<u>10788625</u>	Not Issued	030	02/26/2004	HUMANIZED CHICKEN ANTIBODIES	TSURUSHITA, NAOYA
<u>10822300</u>	Not Issued	030	04/09/2004	ALTERATION OF FCRN BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS	TSURUSHITA, NAOYA
<u>10966673</u>	Not Issued	019	10/15/2004	ALTERATION OF FC-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS	TSURUSHITA, NAOYA
<u>60110523</u>	Not Issued	159	12/01/1998	HUMANIZED ANTIBODIES TO GAMMA-INTERFERON	TSURUSHITA, NAOYA
<u>60120312</u>	Not Issued	159	02/16/1999	NOVEL CHEMOKINE AND USES THEREOF	TSURUSHITA, NAOYA
<u>60178473</u>	Not Issued	159	01/27/2000	ANTIBODIES AGAINST CTLA4 AND USES THEREFOR	TSURUSHITA, NAOYA
<u>60287539</u>	Not Issued	159	04/30/2001	HUMANIZED ANTIBODIES	TSURUSHITA, NAOYA
<u>60307973</u>	Not Issued	159	07/26/2001	INTERLEUKIN-1 BETA ANTIBODIES	TSURUSHITA, NAOYA
<u>60312278</u>	Not Issued	159	08/14/2001	INTERLEUKIN-1 BETA ANTIBODIES	TSURUSHITA, NAOYA
<u>60313224</u>	Not Issued	159	08/17/2001	ANTI-AB ANTIBODIES	TSURUSHITA, NAOYA
<u>60418972</u>	Not Issued	159	10/15/2002	ALTERATION OF FCRN BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS	TSURUSHITA, NAOYA
<u>60451622</u>	Not Issued	159	02/28/2003	HUMANIZED CHICKEN ANTIBODIES	TSURUSHITA, NAOYA
<u>60462014</u>	Not Issued	159	04/10/2003	ALTERATION OF FCRN BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS	TSURUSHITA, NAOYA
<u>60475762</u>	Not Issued	159	06/03/2003	ALTERATION OF FCRN BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY	TSURUSHITA, NAOYA

				MUTAGENESIS	
<u>60489187</u>	Not Issued	159	07/21/2003	EXPRESSION OF PERIOSTIN IS INDUCED BY IL-4 AND IL-13 IN PRIMARY ENDOTHELIAL CELLS	TSURUSHITA, NAOYA
<u>60497474</u>	Not Issued	159	08/21/2003	HUMANIZED ANTI-IP-10 ANTIBODIES AND METHODS OF USING THEREOF FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES	TSURUSHITA, NAOYA
<u>60499048</u>	Not Issued	159	08/29/2003	ALTERATION OF SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS	TSURUSHITA, NAOYA
<u>60511687</u>	Not Issued	159	10/15/2003	ALTERATION OF FC-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS	TSURUSHITA, NAOYA
<u>60511688</u>	Not Issued	159	10/15/2003	ALTERATION OF ANTIBODY COMPLEMENT DEPENDENT CYTOTOXICITY (CDC) ACTIVITY BY MUTAGENESIS	TSURUSHITA, NAOYA
<u>60527882</u>	Not Issued	159	12/04/2003	HUMANIZED ANTI-IP-10 ANTIBODIES AND METHODS OF USING THEREOF FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES	TSURUSHITA, NAOYA
<u>60562627</u>	Not Issued	020	04/14/2004	ALTERATION OF FC-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS	TSURUSHITA, NAOYA

Inventor Search Completed: No Records to Display.

Search Another: Inventor	Last Name	First Name	<input type="button" value="Search"/>
	<input type="text" value="tsurushita"/>	<input type="text" value="naoya"/>	

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Day : Thursday  
Date: 2/24/2005


**PALM INTRANET**

Time: 12:24:34

**Inventor Name Search Result**

Your Search was:

Last Name = HINTON

First Name = PAUL

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<u>10450384</u>	Not Issued	030	12/24/2003	SILENCED ANTI-CD28 ANTIBODIES AND USE THEREOF	HINTON, PAUL
<u>60178473</u>	Not Issued	159	01/27/2000	ANTIBODIES AGAINST CTLA4 AND USES THEREFOR	HINTON, PAUL
<u>60255155</u>	Not Issued	159	12/14/2000	SILENCED ANTI-CD28 ANTIBODIES AND USE THEREOF	HINTON, PAUL
<u>60287653</u>	Not Issued	159	04/30/2001	HUMANIZED ANTIBODIES	HINTON, PAUL
<u>60418972</u>	Not Issued	159	10/15/2002	ALTERATION OF FCRN BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS	HINTON, PAUL
<u>08458666</u>	<u>6218149</u>	150	06/02/1995	ANTIBODIES HAVING MODIFIED CARBOHYDRATE CONTENT AND METHODS OF PREPARATION AND USE	HINTON, PAUL R
<u>09772103</u>	Not Issued	071	01/26/2001	ANTIBODIES AGAINST CTLA4 AND USES THEREFOR	HINTON, PAUL R.
<u>09835461</u>	Not Issued	161	04/16/2001	ANTIBODIES HAVING MODIFIED CARBOHYDRATE CONTENT AND METHODS OF PREPARATION AND USE	HINTON, PAUL R.
<u>10371483</u>	Not Issued	030	02/21/2003	ANTI-CCR5 ANTIBODY	HINTON, PAUL R.
<u>10687118</u>	Not Issued	030	10/15/2003	ALTERATION OF FCRN BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS	HINTON, PAUL R.
<u>10774076</u>	Not	071	02/06/2004	AMPHIREGULIN ANTIBODIES	HINTON, PAUL R.

	Issued			AND THEIR USE TO TREAT CANCER AND PSORIASIS	
<u>10822300</u>	Not Issued	030	04/09/2004	ALTERATION OF FCRN BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS	HINTON, PAUL R.
<u>10966673</u>	Not Issued	019	10/15/2004	ALTERATION OF FC-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS	HINTON, PAUL R.
<u>60462014</u>	Not Issued	159	04/10/2003	ALTERATION OF FCRN BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS	HINTON, PAUL R.
<u>60475762</u>	Not Issued	159	06/03/2003	ALTERATION OF FCRN BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS	HINTON, PAUL R.
<u>60499048</u>	Not Issued	159	08/29/2003	ALTERATION OF SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS	HINTON, PAUL R.
<u>60511687</u>	Not Issued	159	10/15/2003	ALTERATION OF FC-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS	HINTON, PAUL R.
<u>60511688</u>	Not Issued	159	10/15/2003	ALTERATION OF ANTIBODY COMPLEMENT DEPENDENT CYTOTOXICITY (CDC) ACTIVITY BY MUTAGENESIS	HINTON, PAUL R.
<u>60562627</u>	Not Issued	020	04/14/2004	ALTERATION OF FC-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS	HINTON, PAUL R.
<u>07244744</u>	Not Issued	166	09/15/1988	ANTIBODIES HAVING MODIFIED CARBOHYDRATE CONTENT AND METHODS OF PREPARATION AND USE	HINTON, PAUL R.
<u>07260558</u>	Not Issued	166	10/17/1988	ANTI-LEU 3A AMINO ACID SEQUENCE	HINTON, PAUL R.
<u>07938557</u>	Not Issued	166	08/28/1992	ANTIBODIES HAVING MODIFIED CARBOHYDRATE CONTENT AND METHODS OF PREPARATION AND USE	HINTON, PAUL R.
<u>08251529</u>	Not Issued	166	05/31/1994	ANTIBODIES HAVING MODIFIED CARBOHYDRATE	HINTON, PAUL R.

				CONTENT AND METHODS OF PREPARATION AND USE	
<u>10497475</u>	Not Issued	019	01/01/0001	HUMANIZED ANTIBODIES	HINTON, PAUL ROBERT

**Inventor Search Completed:** No Records to Display.

---

**Search Another: Inventor**

Last Name	First Name	
<input type="text" value="hinton"/>	<input type="text" value="paul"/>	<input type="button" value="Search"/>

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Day : Thursday

Date: 2/24/2005

Time: 12:25:18

 **PALM INTRANET****Inventor Name Search Result**

Your Search was:

Last Name = KUMAR

First Name = SHANKAR

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<a href="#">10425195</a>	Not Issued	030	04/29/2003	METHOD AND SYSTEM FOR GENERATING DOCUMENT PACKAGES FOR COMPLEX ENGINEERED EQUIPMENT AND MIXED APPARATUS ORDERS	KUMAR, SHANKAR
<a href="#">10774076</a>	Not Issued	071	02/06/2004	AMPHIREGULIN ANTIBODIES AND THEIR USE TO TREAT CANCER AND PSORIASIS	KUMAR, SHANKAR
<a href="#">10788625</a>	Not Issued	030	02/26/2004	HUMANIZED CHICKEN ANTIBODIES	KUMAR, SHANKAR

**Inventor Search Completed: No Records to Display.**

**Search Another: Inventor**

<b>Last Name</b>	<b>First Name</b>	
<input type="text" value="kumar"/>	<input type="text" value="shankar"/>	<input type="button" value="Search"/>

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)